

Please type a plus sign (+) inside this box



(Modified) PTO/SB/21 (8-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>TRANSMITTAL FORM</p> <p>(to be used for all correspondence after initial filing)</p> <p>RECEIVED JAN 31 2002 FEE CENTER 1600 2002</p>		Application Number	09/874,350
		Filing Date	June 4, 2001
		First Named Inventor	Beverly S. Packard
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	300-903840US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	74 References Enclosed

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Tom Hunter Reg. No. 38,498 The Law Offices of Jonathan Alan Quine
Signature	
Date	11 Jan 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: Jan 15, 2002			
Typed or printed name	Chianti Appling		
Signature		Date	01/15/02



I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231

On Jan 15, 2002

The Law Offices of Jonathan Alan Quine

By [Signature]
Chianti Appling

RECEIVED
FEB 05 2002
TECH CENTER 1600/2900

Attorney Docket No. 300-903840US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Beverly S. Packard, *et al.*

Application No.: 09/874,350

Filed: June 4, 2001

For: COMPOSITIONS FOR THE
DETECTION OF ENZYME ACTIVITY
IN BIOLOGICAL SAMPLES AND
METHODS OF USE THEREOF

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Tom Hunter
Reg. No. 38,498

THE LAW OFFICES OF JONATHAN ALAN QUINE
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

TH:ca



RECEIVED COPY
FEB 05 2002
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231

On JAN 15, 2002

The Law Offices of Jonathan Alan Quine

By [Signature]
Chianti Applig

Attorney Docket No. 300-903840US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Beverly S. Packard, *et al.*

Application No.: 09/874,350

Filed: June 4, 2001

For: COMPOSITIONS FOR THE
DETECTION OF ENZYME ACTIVITY
IN BIOLOGICAL SAMPLES AND
METHODS OF USE THEREOF

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Hunter', with a long horizontal flourish extending to the right.

Tom Hunter
Reg. No. 38,498

THE LAW OFFICES OF JONATHAN ALAN QUINE
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

TH:ca

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number 09/874,350
Filing Date June 4, 2001
First Named Inventor Beverly S. Packard
Group Art Unit Unassigned
Examiner Name Unassigned
Attorney Docket Number 300-903840US

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	AA	4,577,862		Mangel et al	03-25-1986	
	AB	4,648,892		Roux	03-10-1987	
	AC	4,708,929		Henderson	11-24-1987	
	AD	4,780,421		Kameda et al.	10-25-1988	
	AE	4,897,444		Byrnes et al.	01-30-1990	
	AF	5,212,298		Rademacher et al.	05-18-1993	
	AG	5,605,809		Komoriya et al.	02-25-1995	
	AH	5,714,392		Komoriya et al.	02-03-1998	
	AI	5,723,288		Dykstra et al.	03-03-1998	
	AJ	5,804,395		Schade et al.	09-08-1998	
	AK	6,037,137		Komoriya et al.	03-14-2000	
	AL	6,150,097		Tyagi et al.	11/21/2000	
	AM	6,103,476		Tyagi et al.	08/15/2000	
	AN	6,037,103		Tyagi et al.	03/14/2000	
	AO	5,925,517		Tyagi et al.	07/20/1999	
	AP	5,807,674		Tyagi et al.	09/15/1998	
	AQ	5,759,773		Tyagi et al.	06/02/1998	
	AR	5,652,107		Lizardi et al.	07/29/1997	
	AS	5,118,801		Lizardi et al.	06/02/1992	
	AT	5,312,728		Lizardi et al.	05/17/1994	
	AU	6,150,097		Tyagi et al.	11/21/2000	
	AV	6,130,476		Tyagi et al.	08/15/2000	
	AW	6,037,130		Tyagi et al.	03/14/2000	
	AX	5,925,517		Tyagi et al.	07/20/1999	
	AY	5,871,846		Lucas et al.	02/16/1999	
	AZ	5,807,674		Tyagi	09/15/1998	
	BA	5,776,720		Jaffe et al.	07/07/1998	
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
FEB 05 2002
TECH CENTER 1600/2900

Substitute for form 1449A-B/PT

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/874,350
Filing Date	June 4, 2001
First Named Inventor	Beverly S. Packard
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	300-903840US

	BB	5,759,773		Tyagi et al.	06/02/1998	
	BC	5,773,719		Jaffe et al.	03/31/1998	
	BD	5,698,411		Lucas et al.	12/16/1997	
	BE	5,652,107		Lizardi et al.	07/29/1997	
	BF	5,506,115		Toth et al.	04/09/1996	
	BG	5,312,728		Lizardi et al.	05/17/1994	
	BH	5,110,801		Leveen et al.	05/05/1992	
	BI	5,011,910		Marshall et al.	04/30/1991	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	BJ	WO	96/13607		Oncoimmunin, Inc.	05-09-1996		
	BK	WO	00/06778		The Public Health Research Institute of the City of New York, Inc.	02/10/2000		
	BL	WO	98/10096		The Public Health Research Institute of the City of New York, Inc.	03/12/1998		
	BM	WO	00/71740 A1		The Public Health Research Institute of the City of New York, Inc.	11/30/2000		
	BN	WO	00/71562 A1		The Public Health Research Institute of the City of New York, Inc.	11/30/2000		
	BO	WO	01/31062 A1		The Public Health Research Institute of the City of New York, Inc.	05/03/2001		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		09/874,350	
				Filing Date		June 4, 2001	
				First Named Inventor		Beverly S. Packard	
				Group Art Unit		Unassigned	
				Examiner Name		Unassigned	
				Attorney Docket Number		300-903840US	
	BP	WO	97/39008	The Public Health Research Institute of the City of New York, Inc.			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
	BQ	KNIGHT ET AL. "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases." <i>FEBBS LETTERS</i> 296(3):263-266 (1992)					
	BR	CARMEL ET AL. "Use of Substrates with Fluorescent Donor and Acceptor Chromophores for the Kinetic Assay of Hydrolases." <i>FEBBS LETTERS</i> 30(1):11-14 (1973)					
	BS	ISAAC ET AL. "Use of Fluorescence Resonance Energy Transfer to Estimate Intramolecular Distances in the Msx-1 Homeodomain." <i>Biochemistry</i> 34(1):15276-15281 (1995)					
	BT	KELLER ET AL. "Mode of Insertion of the Signal Sequence of a Bacterial Precursor Protein into Phospholipid Bilayers As Revealed by Cysteine-Based Site Directed Spectroscopy." <i>Biochemistry</i> 35:3063-3071 (1996)					
	BU	LATT ET AL. "Fluorescence Determination of Carboxypeptidase A Activity Based on Electronic Energy Transfer." <i>Analytical Biochemistry</i> 50:56 (1972)					
	BV	MATAYOSHI ET AL. "Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer." <i>Science</i> 247 (1990)					
	BW	MATSUZAKI ET AL. "Translocation of a Channel-Forming Antimicrobial Peptide, Maganin 2, across Lipid Bilayers by Forming a Pore." <i>Biochemistry</i> 34:6521-6526 (1995)					
	BX	NAGASE ET AL. "Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix Metalloproteinase-3)" <i>J. of Biol. Chem</i> 269:20952 (1994)					
	BY	PACKARD ET AL. Intramolecular Excitonic Dimers in Protease Substrates: Modification of the Backbone Moiety to Probe the H-Dimer Structure." <i>American Chem Society</i> 1-8 (1998)					
	BZ	PARKHURST ET AL. "Donor-Acceptor Distance Distributions in a Double-Labeled Fluorescent Oligonucleotide Both as a Single Strand and in Duplexes." <i>Biochemistry</i> 34(1):293-300					
	CA	PARKHURST ET AL. "Kinetic Studies by Fluorescence Resonance Energy Transfer Employing a Double-Labeled Oligonucleotide: Hybridization to the Oligonucleotide Complement and to Single Strand DNA" <i>Biochemistry</i> 34:285-292 (1995)					
	CB	WANG ET AL. "Design and Synthesis of New Fluorogenic HIV Protease Substrates Based on Resonance Energy Transfer." <i>Tetrahedron Letters</i> 31:6493 (1990)					
	CC	WU ET AL. "Resonance Energy Transfer: Methods and Applications." <i>Analytical Biochemistry</i> 218:1-13 (1994)					
	CD	YANG ET AL. "Conformational Flexibility of Three-Way DNA Junctions Containing Impaired Nucleotides." <i>Biochemistry</i> 35:7959-7967 (1996)					
	CE	FINUCANE ET AL. "Bax-induced Caspase Activation and Apoptosis via Cytochrome c Release from Mitochondria Is Inhibitable by Bcl-xL" Abstract J Biol Chem, Vol. 274, Issue 4, 2225-2233, January 22, 1999					
	CF	KANUKA ET AL. "Proapoptotic activity of Caenorhabditis elegans CED-4 protein in Drosophila: Implicated mechanisms for caspase activation" Proc. Natl. Acad. Sci. USA Vol. 96, pp. 145-150, January 1999					
Examiner Signature						Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
FEB 05 2002
TECH CENTER 1600-16300

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/874,350
		Filing Date	June 4, 2001
		First Named Inventor	Beverly S. Packard
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	300-903840US
CG	HARVEY ET AL. "Caspase-dependent Cdk Activity Is a Requisite Effector of Apoptotic Death Events" Jol. Of Cell Biol. Vol. 148, No. 1, January 10, 2000		
CH	EKERT ET AL. "Inhibition of Apoptosis and Clonogenic Survival of Cells Expressing crmA Variants: Optimal Caspase Substrates are Not Necessarily Optimal Inhibitors" EMBO Jol. Vol. 18, No. 2, 330-338, (1999)		
CI	ROBLES ET AL. "Localization, Regulation and Possible Consequences of Apoptotic Protease-Activating Factor-1 (Apaf-1) Expression in Granulosa Cells of the Mouse Ovary" Abstract Endocrinology June 1999		
CJ	PEREZ ET AL. "Fragmentation and Death (aka apoptosis) of Ovulated Oocytes" Molecular Human Reproduction Vol 5, No. 5, 414-420, (1999)		
CK	ZAPATA ET AL. "Granzyme Release and Caspase Activation in Activated Human T-Lymphocytes" Jol. Of Biol. Chem. Vol. 273, No. 12, pp. 6916-6920 (1998)		
CL	SIEGEL ET AL. "Death-Effector Filaments: Novel Cytoplasmic Structures that Recruit Caspases and Trigger Apoptosis" Jol. Of Cell Biol. Vol. 141, No. 5, June 1, 1998		
CM	HIRATA ET AL. "Caspases Are Activated in a Branched Protease Cascade and Control Distinct Downstream Processes in Fas-Induced Apoptosis" J. of Exp. Med. Vol. 187, No. 4, February 16, 1998		
CN	KOMORIYA ET AL. "Assessment of Caspase Activities in Intact Apoptotic Thymocytes Using Cell-Permeable Fluorogenic Caspase Substrates" J. of Exp. Med. Vol. 191, No. 11, 1819-1828, June 5, 2000		
CO	KOMORIYA "Single-Cell Image-Based Cellular Protease" Cambridge Health Institute's Eighth Annual HTTP Expo, June 2001		
CP	PACKARD ET AL. "Intramolecular Excitonic Dimers in Protease Substrates: Modification of the Backbone Moiety to Probe the H-Dimer Structure" J. Phys. Chem. B pp. 1820-1827 1998		
CQ	PACARD ET AL. "Intramolecular Resonance Dipole-Dipole Interactions in a Profluorescent Protease" J. Phys. Chem. B, pp. 752-758, 1998		
CR	PACKARD ET AL. "Characterization of Fluorescence Quenching in Bifluorophoric Protease Substrates", Biochemical Chemistry 67 (1997) 167-176		
CS	PACKARD ET AL. "Structural Characteristics of Fluorophores that Form Intramolecular H-Type Dimers in a Protease Substrate", J. Phys. Chem. B (1997) 101, 5070-5074		
CT	PACKARD ET AL. "Design of Profluorescent Protease Substrates Guided by Exciton Theory", Methods in Enzymology, Vol. 278, 15-28, (1997)		
CU	PACKARD ET AL. "Profluorescent Protease Substrates: Intramolecular Dimers Described by the Exciton Model", Proc. Natl. Acad. Sci. Vol. 93, pp. 11640-11645, October 1996		
CV	PACKARD ET AL. "Profluorescent Substrates for Protease Activity Detection Ground-State Xanthene or Resonance Energy Transfer", Abstracts 40 th Annual Meeting, Baltimore, MD February 1996		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.